Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
WuXi Biologics (Cayman)'s book value per share for the quarter that ended in Dec. 2025 was $1.62.
During the past 12 months, WuXi Biologics (Cayman)'s average Book Value Per Share Growth Rate was 16.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 66.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of WuXi Biologics (Cayman) was 262.10% per year. The lowest was 5.40% per year. And the median was 55.50% per year.
During the past 12 years, the highest P/B Ratio of WuXi Biologics (Cayman) was 176.03. The lowest was 0.99. And the median was 8.76.
WuXi Biologics (Cayman) (OTCPK:WXIBF) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
WuXi Biologics (Cayman) Book Value per Share Related Terms
WuXi Biologics (Cayman) Book Value per Share Historical Data
* Premium members only.
The historical data trend for WuXi Biologics (Cayman)'s Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) Book Value per Share Chart
WXIBF vs VRTX, REGN, ALNY: Book Value per Share Comparison
For the Biotechnology subindustry, WuXi Biologics (Cayman)'s PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WuXi Biologics (Cayman) PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s PB Ratio distribution charts can be found below:
* The bar in red indicates where WuXi Biologics (Cayman)'s PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WuXi Biologics (Cayman) (WXIBF) has a Book Value per Share of $1.62 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on WuXi Biologics (Cayman) and its competitors.
Is WuXi Biologics (Cayman)'s Book Value per Share too high?
WuXi Biologics (Cayman)'s current Book Value per Share is $1.62. Overall, WuXi Biologics (Cayman) has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WuXi Biologics (Cayman)'s Book Value per Share compare to VRTX and REGN?
WuXi Biologics (Cayman)'s Book Value per Share of $1.62 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on WuXi Biologics (Cayman) and its competitors. WuXi Biologics (Cayman)'s current Book Value per Share is $1.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WuXi Biologics (Cayman) stock overvalued right now?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) (WXIBF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.16, compared to a current price of $4.60 — trading 10.9% below its estimated fair value. The current Book Value per Share is $1.62. WuXi Biologics (Cayman)'s overall GF Score™ is 97/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For WuXi Biologics (Cayman) (WXIBF), the current Book Value per Share is $1.62 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WuXi Biologics (Cayman) (WXIBF) Overvalued in 2026?
Based on GuruFocus' analysis, WuXi Biologics (Cayman) stock appears to be undervalued.
The current stock price of $4.60 is trading 10.9% below its estimated GF Value™ of $5.16.
GuruFocus considers WuXi Biologics (Cayman) to be Modestly Undervalued.
Key valuation signals for WXIBF:
Book Value per Share: $1.62
GF Value™: $5.16 vs. price of $4.60 (10.9% below fair value)
No single metric tells the full story. See the WXIBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WuXi Biologics is one of the largest biologics contract development and manufacturing organizations in the world. Incorporated in 2014 following the reorganization of WuXi PharmaTech, WuXi engages in full-lifecycle services beginning from drug discovery, clinical trials, and commercial manufacturing. It focuses on developing refining and manufacturing processes to increase scalability and efficiency for pharmaceutical companies looking to outsource and access specialized knowledge. As of 2024, WuXi derives more than 60% of its revenue from US companies and focuses its operations on high-growth, late-stage, and commercial projects in the biologics sector. WuXi competes with Samsung Biologics, Lonza, and Fujifilm for contracts.
97GF Score
Get the complete analysis for WXIBF
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WXIBF has been successfully added to your 
